Pulmonology

Eight US Manufacturers Selected to Make NASA COVID-19 Ventilator

Friday, May 29, 2020 - 8:14pm

WASHINGTON, May 29, 2020 /PRNewswire/ --After receiving more than 100 applications, NASA's Jet Propulsion Laboratory (JPL) in Southern California has selected eight U.S. manufacturers to make a new ventilator tailored for coronavirus (COVID-19) patients.

Key Points: 
  • WASHINGTON, May 29, 2020 /PRNewswire/ --After receiving more than 100 applications, NASA's Jet Propulsion Laboratory (JPL) in Southern California has selected eight U.S. manufacturers to make a new ventilator tailored for coronavirus (COVID-19) patients.
  • Called VITAL (Ventilator Intervention Technology Accessible Locally), the high-pressure ventilatorwas designed to use one-seventh the parts of a traditional ventilator, relying on parts already available in supply chains.
  • It offers a simpler, more affordable option for treating critical patients while freeing up traditional ventilators for those with the most severe COVID-19 symptoms.
  • The compressed-air design also has been submitted to the FDA for a ventilator Emergency Use Authorization and is currently under review.

Level Ex® Releases Video Game COVID-19 Levels to Prepare Healthcare Providers

Wednesday, May 27, 2020 - 2:05pm

Level Ex , creator of industry-leading medical video games for physicians, has launched COVID-19 levels within its Airway Ex and Pulm Ex mobile games with support from an educational grant provided by the Johnson & Johnson Institute.

Key Points: 
  • Level Ex , creator of industry-leading medical video games for physicians, has launched COVID-19 levels within its Airway Ex and Pulm Ex mobile games with support from an educational grant provided by the Johnson & Johnson Institute.
  • * These new game levels help pulmonologists, emergency medicine physicians, anesthesiologists, and other healthcare providers navigate challenging COVID-19 patient scenarios and make better emergency decisions.
  • Invested in keeping healthcare providers abreast of vital information during the pandemic, Level Ex will develop more levels addressing COVID-19 treatment, management, and comorbidities.
  • The COVID-19 levels are available for free through the Airway Ex and Pulm Ex mobile games on Google Play.

COVID-19 Impact on Global Neonatal Ventilator Market - Research Dive

Tuesday, May 26, 2020 - 1:00pm

Conversely, high costs associated with neonatal ventilator system is expected to hamper the market growth during the forecast period.

Key Points: 
  • Conversely, high costs associated with neonatal ventilator system is expected to hamper the market growth during the forecast period.
  • On the basis of product type, the global market for neonatal ventilator is segmented into non-invasive and invasive ventilation.
  • Based on the technology, the neonatal ventilator market is segmented into mechanical ventilator, hybrid ventilator, volume targeted ventilator, and high frequency ventilator.
  • On the basis of mobility type, the global market for neonatal ventilator market is segmented into portable/transportable ventilators and intensive care ventilators.

COVID-19 Impact on Global Neonatal Ventilator Market - Research Dive

Tuesday, May 26, 2020 - 1:00pm

Conversely, high costs associated with neonatal ventilator system is expected to hamper the market growth during the forecast period.

Key Points: 
  • Conversely, high costs associated with neonatal ventilator system is expected to hamper the market growth during the forecast period.
  • On the basis of product type, the global market for neonatal ventilator is segmented into non-invasive and invasive ventilation.
  • Based on the technology, the neonatal ventilator market is segmented into mechanical ventilator, hybrid ventilator, volume targeted ventilator, and high frequency ventilator.
  • On the basis of mobility type, the global market for neonatal ventilator market is segmented into portable/transportable ventilators and intensive care ventilators.

Deborah Heart and Lung Center Introduces Remote Patient Monitoring for COPD Patients

Tuesday, May 26, 2020 - 12:00pm

BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).

Key Points: 
  • BROWNS MILLS, N.J., May 26, 2020 /PRNewswire-PRWeb/ --Deborah Heart and Lung Center, New Jersey's only specialty heart, lung, and vascular hospital, and an Alliance member of the Cleveland Clinic Heart, Vascular & Thoracic Institute, has announced the introduction of remote patient monitoring for patients diagnosed with chronic obstructive pulmonary disease (COPD).
  • Patients diagnosed with COPD require physician monitoring to prevent the disease from progressing.
  • With the expansion of telemedicine and remote monitoring services prompted by the Coronavirus epidemic, Deborah has instituted a new remote patient monitoring services platform.
  • Called HGE Care the remote monitoring platform is designed for COPD patients who have been discharged from the hospital and are recuperating at home.

OFEV® (nintedanib) now available in Canada for adults living with progressive fibrosing interstitial lung diseases (PF-ILD)(1)

Monday, May 25, 2020 - 1:00pm

This new indication is a part of the company's ongoing commitment to improving the lives of people living with ILDs.

Key Points: 
  • This new indication is a part of the company's ongoing commitment to improving the lives of people living with ILDs.
  • Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
  • Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
  • Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.

Global Ventilator Market Report 2020-2025: Featuring Profiles of Key Players Medtronic, Zoll Medical, Getinge AB, Allied Healthcare Products and Air Liquide

Friday, May 22, 2020 - 8:00pm

DUBLIN, May 22, 2020 /PRNewswire/ -- The "Ventilator Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, May 22, 2020 /PRNewswire/ -- The "Ventilator Market - Forecasts from 2020 to 2025" report has been added to ResearchAndMarkets.com's offering.
  • The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.
  • The rise in cases of respiratory emergencies and Chronic Obstructive Pulmonary Disease (COPD) are the major factors, which are strengthening the growth of global ventilator market.
  • The "Ventilator Market - Forecasts from 2020 to 2025" report segments the industry as follows:

Global Ventilator Market 2020: Innovation is Key to Meet Surge in Demand from COVID-19 - ResearchAndMarkets.com

Thursday, May 21, 2020 - 10:21am

The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.

Key Points: 
  • The ventilator market is projected to grow at a CAGR of 5.53% to reach US$3,095.180 million by 2025 from US$2,240.940 million in 2019.
  • The rise in cases of respiratory emergencies and Chronic Obstructive Pulmonary Disease (COPD) are the major factors, which are strengthening the growth of global ventilator market.
  • For example in light of the global pandemic that has gripped our planet and the impact that has permeated every aspect of human, innovation has been key.
  • The "Ventilator Market - Forecasts from 2020 to 2025" report segments the industry as follows:

National Jewish Health Announces Call for Abstracts For Respiratory Disease Young Investigators' Forum

Wednesday, May 20, 2020 - 11:26pm

The goal of the Respiratory Disease Young Investigators' Forum is to increase the number of physician-scientists through a program for fellows and early career faculty that includes mentoring,peer networking, coaching, scientific presentation skills, education and encouragement.

Key Points: 
  • The goal of the Respiratory Disease Young Investigators' Forum is to increase the number of physician-scientists through a program for fellows and early career faculty that includes mentoring,peer networking, coaching, scientific presentation skills, education and encouragement.
  • The Forum provides the opportunity to present research to a panel of national experts in respiratory medicine who serve as mentors and real-world examples of physician-scientists who have had an impact on respiratory medicine through their research.
  • National Jewish Health the nation's leading respiratory hospital, is committed to developing the next generation of physician-scientists through the sponsorship of the Respiratory Disease Young Investigators' Forum.
  • Patients and families come to National Jewish Health from around the world to receive cutting-edge, comprehensive, coordinated care.

OliX Pharmaceuticals Presents at BIO KOREA 2020 International Convention

Wednesday, May 20, 2020 - 1:00pm

SUWON, Republic of Korea, May 20, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals , Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced that Dong-Ki Lee, Ph.D., founder and Chief Executive Officerpresented the Companys platform technology and discussed the potential utility of siRNA therapeutics in combatting COVID-19 at BIO KOREA 2020 .

Key Points: 
  • SUWON, Republic of Korea, May 20, 2020 (GLOBE NEWSWIRE) -- OliX Pharmaceuticals , Inc. (KOSDAQ: 226950), a key player in the development of RNAi therapeutics, today announced that Dong-Ki Lee, Ph.D., founder and Chief Executive Officerpresented the Companys platform technology and discussed the potential utility of siRNA therapeutics in combatting COVID-19 at BIO KOREA 2020 .
  • OliX has established a pulmonary RNAi platform via inhalation delivery to develop therapy for idiopathic pulmonary fibrosis and other pulmonary diseases.
  • Cell-Penetrating Asymmetric Interfering RNA (cp-asiRNA) is OliX Pharmaceuticals proprietary RNAi delivery method that efficiently silences gene expressions.
  • In March 2020, OliX Pharmaceuticals secured a proprietary N-Acetylgalactosamine (GalNAc) platform, a RNAi therapy platform that targets variety of liver diseases.